Skip to main content

Table 2 Basic research parameters

From: Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?

Research parameters

Aducanumab

SoC

References

Disturubution

Costs-Annual ($)

Mild $22,000*

Mild $3,140#

Moderate $9,460#

Severe $16.956#

*[17] #[34]

Gamma

Effectiveness data

Mild 0.73

Mild 0.73

Moderate 0.69

Severe 0.27

[35]

Beta

Model and transition probabilities

See Fig. 1, Table 1

See Fig. 1, Table 1

[32]

Beta

Number of cohorts

1000

1000

 

NA

Clinical efficacy data

RR = 0.6

–

Assumption

NA

Horizon

5 year

5 year

 

NA

Discount Rate

6%

6%

[37]

(3–9%)

Threshold Value+

$28,617

$28,617

[38]

NA

Perspective

Patient

Patient

 

–

  1. NA: Not assessed
  2. +Calculated based on 2022 GDP
  3. *Aducanumab annual cost
  4. #SoC annual cost